Anaplastic thyroid carcinoma: current trends and future perspectives

Detalhes bibliográficos
Autor(a) principal: Valente, Miguel F.
Data de Publicação: 2017
Outros Autores: Capela-Costa, João
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://revista.spcir.com/index.php/spcir/article/view/672
Resumo: Anaplastic thyroid carcinoma is a rare neoplasm (constituting about 2% of thyroid tumors) but highly lethal. Despite recent advances in the management of the disease and the establishment of multimodal treatments, the results continue to be bleak with the median survival of around 5-6 months after diagnosis. The search for new methods to earlier diagnosis as well as for new therapeutic targets both effective and safe is the key to improve the prognosis of these patients. The last decade has brought us important discoveries, especially in understanding the molecular mechanisms of tumor dedifferentiation, representing good potential to increase the sensitivity of diagnostics tests and find new drugs. The latest options in molecular treatment are kinase inhibitors, anti-angiogenic drugs, proteasome inhibitors and epigenetic drugs (histone deacetylase inhibitors and demethylating agents). The results of some phase II studies are promising. This paper reviews the diagnostic and therapeutic tools currently used and presents some of the latest discoveries in the treatment of patients with anaplastic thyroid carcinoma.
id RCAP_8216b2b9b932a37bcf4193ee4db3559c
oai_identifier_str oai:revista.spcir.com:article/672
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Anaplastic thyroid carcinoma: current trends and future perspectivesCarcinoma anaplásico da tiróide: tendências atuais e perspetivas futurasAnaplastic thyroid carcinoma is a rare neoplasm (constituting about 2% of thyroid tumors) but highly lethal. Despite recent advances in the management of the disease and the establishment of multimodal treatments, the results continue to be bleak with the median survival of around 5-6 months after diagnosis. The search for new methods to earlier diagnosis as well as for new therapeutic targets both effective and safe is the key to improve the prognosis of these patients. The last decade has brought us important discoveries, especially in understanding the molecular mechanisms of tumor dedifferentiation, representing good potential to increase the sensitivity of diagnostics tests and find new drugs. The latest options in molecular treatment are kinase inhibitors, anti-angiogenic drugs, proteasome inhibitors and epigenetic drugs (histone deacetylase inhibitors and demethylating agents). The results of some phase II studies are promising. This paper reviews the diagnostic and therapeutic tools currently used and presents some of the latest discoveries in the treatment of patients with anaplastic thyroid carcinoma.O carcinoma anaplásico da tiróide é uma neoplasia muito rara, constituindo cerca de 2% dos tumores da tiróide, mas o mais letal de todos. Apesar dos recentes avanços na abordagem da doença e do recurso a tratamentos multimodais, os resultados continuam a ser desoladores com a sobrevida média a rondar os 5-6 meses após o diagnóstico. A pesquisa de novos métodos que permitam o diagnóstico mais precoce dos doentes bem como de novos alvos terapêuticos que sejam tão eficazes quanto seguros é fundamental para melhorar o prognóstico destes pacientes. A última década trouxe-nos descobertas importantes, sobretudo na compreensão dos mecanismos moleculares da desdiferenciação tumoral, que representam boas hipóteses de aumentar a sensibilidade dos meios de diagnóstico e de encontrar novos fármacos para o controlo da doença. As últimas opções no tratamento molecular são inibidores da cinase, anti-angiogénicos, inibidores do proteossoma e fármacos epigenéticos (inibidores da deacetilase das histonas e agentes hipometilizantes). Os resultados de alguns estudos de fase II parecem promissores. Este trabalho revê as ferramentas de diagnóstico e terapêutica utilizadas atualmente e apresenta algumas das descobertas mais recentes no âmbito do tratamento dos doentes com carcinoma anaplásico da tiróide.Sociedade Portuguesa de Cirurgia2017-10-10info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://revista.spcir.com/index.php/spcir/article/view/672Revista Portuguesa de Cirurgia; No 41 (2017): Number 41 - June 2017; 29 - 39Revista Portuguesa de Cirurgia; No 41 (2017): Number 41 - June 2017; 29 - 392183-11651646-6918reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spcir.com/index.php/spcir/article/view/672https://revista.spcir.com/index.php/spcir/article/view/672/503Copyright (c) 2017 Revista Portuguesa de Cirurgiainfo:eu-repo/semantics/openAccessValente, Miguel F.Capela-Costa, João2024-03-14T22:04:36Zoai:revista.spcir.com:article/672Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T04:00:39.864955Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Anaplastic thyroid carcinoma: current trends and future perspectives
Carcinoma anaplásico da tiróide: tendências atuais e perspetivas futuras
title Anaplastic thyroid carcinoma: current trends and future perspectives
spellingShingle Anaplastic thyroid carcinoma: current trends and future perspectives
Valente, Miguel F.
title_short Anaplastic thyroid carcinoma: current trends and future perspectives
title_full Anaplastic thyroid carcinoma: current trends and future perspectives
title_fullStr Anaplastic thyroid carcinoma: current trends and future perspectives
title_full_unstemmed Anaplastic thyroid carcinoma: current trends and future perspectives
title_sort Anaplastic thyroid carcinoma: current trends and future perspectives
author Valente, Miguel F.
author_facet Valente, Miguel F.
Capela-Costa, João
author_role author
author2 Capela-Costa, João
author2_role author
dc.contributor.author.fl_str_mv Valente, Miguel F.
Capela-Costa, João
description Anaplastic thyroid carcinoma is a rare neoplasm (constituting about 2% of thyroid tumors) but highly lethal. Despite recent advances in the management of the disease and the establishment of multimodal treatments, the results continue to be bleak with the median survival of around 5-6 months after diagnosis. The search for new methods to earlier diagnosis as well as for new therapeutic targets both effective and safe is the key to improve the prognosis of these patients. The last decade has brought us important discoveries, especially in understanding the molecular mechanisms of tumor dedifferentiation, representing good potential to increase the sensitivity of diagnostics tests and find new drugs. The latest options in molecular treatment are kinase inhibitors, anti-angiogenic drugs, proteasome inhibitors and epigenetic drugs (histone deacetylase inhibitors and demethylating agents). The results of some phase II studies are promising. This paper reviews the diagnostic and therapeutic tools currently used and presents some of the latest discoveries in the treatment of patients with anaplastic thyroid carcinoma.
publishDate 2017
dc.date.none.fl_str_mv 2017-10-10
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://revista.spcir.com/index.php/spcir/article/view/672
url https://revista.spcir.com/index.php/spcir/article/view/672
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revista.spcir.com/index.php/spcir/article/view/672
https://revista.spcir.com/index.php/spcir/article/view/672/503
dc.rights.driver.fl_str_mv Copyright (c) 2017 Revista Portuguesa de Cirurgia
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2017 Revista Portuguesa de Cirurgia
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Cirurgia
publisher.none.fl_str_mv Sociedade Portuguesa de Cirurgia
dc.source.none.fl_str_mv Revista Portuguesa de Cirurgia; No 41 (2017): Number 41 - June 2017; 29 - 39
Revista Portuguesa de Cirurgia; No 41 (2017): Number 41 - June 2017; 29 - 39
2183-1165
1646-6918
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138181930549248

Registros relacionados